Litcius/Paper detail

Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs

Yuta Suzuki, Hiroshi Ishihara

2021Drug Metabolism and Pharmacokinetics281 citationsDOIOpen Access PDF

Topics & Concepts

Coronavirus disease 2019 (COVID-19)VirologyMedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Messenger RNANucleic acidBiodistributionCoronavirusPharmacologyBiologyDiseaseGeneInfectious disease (medical specialty)In vitroGeneticsPathologyRNA Interference and Gene DeliverySARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies
Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs | Litcius